WO2010096551A3 - Antimicrobial compositions - Google Patents
Antimicrobial compositions Download PDFInfo
- Publication number
- WO2010096551A3 WO2010096551A3 PCT/US2010/024576 US2010024576W WO2010096551A3 WO 2010096551 A3 WO2010096551 A3 WO 2010096551A3 US 2010024576 W US2010024576 W US 2010024576W WO 2010096551 A3 WO2010096551 A3 WO 2010096551A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compositions
- antimicrobial compositions
- crystallization inhibitor
- basifϊer
- basifer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to pharmaceutical compositions comprising a quinolone carboxylic acid compound and an absorption enhancer. In further embodiments, the compositions further comprise a basifer or a crystallization inhibitor, or both a basifϊer and a crystallization inhibitor. These compositions are useful for treating, preventing, or reducing the risk of infection.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15346309P | 2009-02-18 | 2009-02-18 | |
US61/153,463 | 2009-02-18 | ||
US25147509P | 2009-10-14 | 2009-10-14 | |
US61/251,475 | 2009-10-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010096551A2 WO2010096551A2 (en) | 2010-08-26 |
WO2010096551A3 true WO2010096551A3 (en) | 2010-12-16 |
Family
ID=42634437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/024576 WO2010096551A2 (en) | 2009-02-18 | 2010-02-18 | Antimicrobial compositions |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2010096551A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2015011760A (en) | 2013-03-15 | 2016-06-10 | Melinta Therapeutics Inc | Methods of treating infections in overweight and obese patients using antibiotics. |
TW201444558A (en) * | 2013-03-15 | 2014-12-01 | Melinta Therapeutics Inc | Methods of treating gonorrhea infections using quinolone antibiotics |
CN103788366B (en) * | 2014-01-22 | 2015-10-28 | 沈阳药科大学 | Mono methoxy polyethylene glycol-two sulphur-two VE-succinate and Synthesis and applications thereof |
TW201605447A (en) * | 2014-06-20 | 2016-02-16 | 美林塔治療學有限公司 | Methods for treating infections |
TWI732337B (en) * | 2014-06-20 | 2021-07-01 | 美商梅琳塔有限責任公司 | Pharmaceutical composition and use thereof |
CN105693695A (en) * | 2014-11-24 | 2016-06-22 | 重庆医药工业研究院有限责任公司 | Delafloxacin meglumine salt crystal form, and preparation method thereof |
CN107789324B (en) * | 2016-08-31 | 2021-05-25 | 鲁南制药集团股份有限公司 | Delaxacin meglumine for injection and preparation method thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0549857A1 (en) * | 1991-12-31 | 1993-07-07 | Korea Research Institute Of Chemical Technology | Antibacterial quinolone carboxylic acid derivatives |
US20020182255A1 (en) * | 1999-03-31 | 2002-12-05 | Samir Roy | Quinolone carboxylic acid compositions and related methods of treatment |
US20030032600A1 (en) * | 2001-03-05 | 2003-02-13 | Ulrich Stephen A. | Taste masked liquid pharmaceutical compositions |
-
2010
- 2010-02-18 WO PCT/US2010/024576 patent/WO2010096551A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0549857A1 (en) * | 1991-12-31 | 1993-07-07 | Korea Research Institute Of Chemical Technology | Antibacterial quinolone carboxylic acid derivatives |
US20020182255A1 (en) * | 1999-03-31 | 2002-12-05 | Samir Roy | Quinolone carboxylic acid compositions and related methods of treatment |
US20030032600A1 (en) * | 2001-03-05 | 2003-02-13 | Ulrich Stephen A. | Taste masked liquid pharmaceutical compositions |
Non-Patent Citations (3)
Title |
---|
COLLNOT EM ET AL.: "Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers.", J. CONTROL. RELEASE., vol. 111, no. 1-2, 10 January 2006 (2006-01-10), pages 35 - 40 * |
KHOUGAZ K ET AL.: "Clas SD. Crystallization inhibition in solid dispersions of MK-05 91 and poly(vinylpyrrolidone) polymers.", J. PHARM. SCI., vol. 89, no. 10, October 2000 (2000-10-01), pages 1325 - 1334 * |
TOMIOKA H ET AL.: "Comparative antimicrobial activities of the newly synthes ized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.", ANTIMICROB. AGENTS CHEMOTHER., vol. 44, no. 2, February 2000 (2000-02-01), pages 283 - 286 * |
Also Published As
Publication number | Publication date |
---|---|
WO2010096551A2 (en) | 2010-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010096551A3 (en) | Antimicrobial compositions | |
WO2010056872A3 (en) | Antimicrobial compositions | |
WO2008051416A3 (en) | Compounds that inhibit the activity of hsp90 for treating infections | |
WO2011047319A3 (en) | Antimicrobial compounds and methods of making and using the same | |
WO2014028589A3 (en) | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
WO2011047323A3 (en) | Antimicrobial compounds and methods of making and using the same | |
WO2010057101A3 (en) | Compounds useful as hiv blockers | |
WO2012021796A8 (en) | Novel cyclosporin derivatives for the treatment and prevention of a viral infection | |
EP2330894B8 (en) | Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors | |
WO2009147075A3 (en) | Pharmaceutical compositions containing a crystalline form of posaconazole | |
MX2010014041A (en) | A crystalline form of posaconazole. | |
WO2010108187A3 (en) | Compounds and methods for treating mammalian gastrointestinal microbial infections | |
MY162636A (en) | Anti parisitic dihydroazole compounds and compositions comprising same | |
WO2008061724A3 (en) | Compositions comprising carnosic acid 12-methylether | |
WO2010029302A3 (en) | Compounds for treating viral infections | |
NZ596628A (en) | Ketolide compounds having antimicrobial activity | |
WO2008086122A3 (en) | Imidazole derivatives as kinesin spindle protein inhibitors (eg-5) | |
WO2012015986A3 (en) | Substituted dioxopiperidinyl phthalimide derivatives | |
WO2011054741A3 (en) | Crystalline complexes of 4-hydroxy benzoic acid and selected pesticides | |
WO2010031832A3 (en) | Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative | |
WO2011047320A3 (en) | Antimicrobial compounds and methods of making and using the same | |
WO2010039654A3 (en) | Topical treatment of skin infection | |
WO2007110834A3 (en) | Malate salts, and polymorphs of (3s,5s)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid | |
WO2009094560A3 (en) | Thienopyranones as kinase inhibitors | |
WO2011088160A3 (en) | Novel cyp17 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10744292 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10744292 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |